[7] This was based on interim analysis of 134 COVID cases in its Phase III study conducted in Europe and Latin America.

[4] CVnCoV is an mRNA vaccine that encodes the full-length, pre-fusion stabilized coronavirus spike protein, and activates the immune system against it.

[12] Manufacturing of mRNA vaccines can be performed rapidly in high volume,[13] including use of portable, automated printers ("RNA microfactories") for which CureVac has a joint development partnership with Tesla.

[19] In November, CureVac reported results of a Phase I-II clinical trial that CVnCoV (active ingredient zorecimeran) was well-tolerated, safe, and produced a robust immune response.

The modified mRNA induces potent antibodies and other protective immune responses and circumvents the body's inflammatory reactions.

A next-generation vaccine from CureVac in collaboration with GlaxoSmithKline, also using unmodified mRNA, is more stable inside cells and produces higher levels of neutralizing antibodies in animals.